RANK(L) as a key target for controlling bone loss

Advances in Experimental Medicine and Biology

Volumn 647, Issue , 2009, Pages 130-145

  Leibbrandt, Andreas ^a   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENOSUMAB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PROSTAGLANDIN E2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ALBERS SCHOENBERG DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; LANGERHANS CELL; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYNOVIOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; ANIMAL; BONE DISEASE; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; BONE DISEASES; HUMANS; RANK LIGAND;

EID: 77953728107     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-89520-8_9     Document Type: Article

References (125)

1. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2(4):389-406. (Pubitemid 34436569)
2. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T-cells, bone loss and mammalian evolution. Annu Rev Immunol 2002;20:795-823. (Pubitemid 34293440)
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423(6937):337-342. (Pubitemid 40852708)
4. Wada T, Nakashima T, Hiroshi N et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12(1):17-25. (Pubitemid 43089652)
5. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004;351(27):2839-2849.
6. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390(6656):175-179. (Pubitemid 27507987)
7. Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun. N-terminal kinase in T-cells. J Biol Chem 1997;272(40):25190-25194. (Pubitemid 27415705)
8. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-176. (Pubitemid 28180851)
9. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-3602.
10. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139(3):1329-1337. (Pubitemid 28510154)
11. Tsuda E, Goto M, Mochizuki S et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234(1):137-142. (Pubitemid 27267548)
12. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-319. (Pubitemid 27199902)
13. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13(18):2412-2424. (Pubitemid 29453612)
14. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397(6717):315-323.
15. Li J, Sarosi I, Yan XQ et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97(4):1566-1571. (Pubitemid 30118482)
16. Chesneau V, Becherer JD, Zheng Y et al. Catalytic properties of ADAM19. J Biol Chem 2003;278(25):22331-22340. (Pubitemid 36830282)
17. Schlondorff J, Lum L, Blobel CP. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 2001;276(18):14665-14674.
18. Lum L, Wong BR, Josien R et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha) - converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274(19):13613-13618.
19. Ikeda T, Kasai M, Utsuyama M et al. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001;142(4):1419-1426. (Pubitemid 32299669)
20. Lynch CC, Hikosaka A, Acuff HB et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7(5):485-496. (Pubitemid 40719131)
21. Lam J, Nelson CA, Ross FP et al. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 2001;108(7):971-979. (Pubitemid 32946071)
22. Ito S, Wakabayashi K, Ubukata O et al. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem 2002;277(8):6631-6636. (Pubitemid 34968464)
23. Hofbauer LC, Khosla S, Dunstan CR et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15(1):2-12. (Pubitemid 30026926)
24. Chan FK, Chun HJ, Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000;288(5475):2351- 2354. (Pubitemid 30448156)
25. Siegel RM, Frederiksen JK, Zacharias DA et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288(5475):2354-2357. (Pubitemid 30448157)
26. Chan KF, Siegel MR, Lenardo JM. Signaling by the TNF receptor superfamily and T-cell homeostasis. Immunity 2000;13(4):419-422.
27. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104(4):487-501. (Pubitemid 32201945)
28. Tan KB, Harrop J, Reddy M et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells. Gene 1997;204(1-2):35-46. (Pubitemid 28022168)
29. Kwon BS, Wang S, Udagawa N et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12(10):845-854. (Pubitemid 28294674)
30. Bucay N, Sarosi I, Dunstan CR et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12(9):1260-1268. (Pubitemid 28213402)
31. Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247(3):610-615. (Pubitemid 28418439)
32. Nakagawa N, Kinosaki M, Yamaguchi K et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 18 1998;253(2):395-400. (Pubitemid 29026714)
33. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96(7):3540-3545. (Pubitemid 29168945)
34. Hughes AE, Ralston SH, Marken J et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000;24(1):45-48. (Pubitemid 30041418)
35. Whyte MP, Mills BG, Reinus WR et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res 2000;15(12):2330-2344.
36. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002;17(1):26-29. (Pubitemid 33150993)
37. Cundy T, Hegde M, Naot D et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11(18):2119-2127. (Pubitemid 34994000)
38. Chong B, Hegde M, Fawkner M et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003;18(12):2095-2104. (Pubitemid 37463303)
39. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83(3):170-179. (Pubitemid 40487405)
40. Inoue J, Ishida T, Tsukamoto N et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 2000;254(1):14-24. (Pubitemid 30066727)
41. Darnay BG, Haridas V, Ni J et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun. N-terminal kinase. J Biol Chem 1998;273(32):20551-20555. (Pubitemid 28377625)
42. Galibert L, Tometsko ME, Anderson DM et al. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 1998;273(51):34120-34127.
43. Wong BR, Josien R, Lee SY et al. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 1998;273(43):28355-28359. (Pubitemid 28496137)
44. Lee ZH, Kwack K, Kim KK et al. Activation of c-Jun. N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. Mol Pharmacol 2000;58(6):1536-1545.
45. Lomaga MA, Yeh WC, Sarosi I et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling. Genes Dev 1999;13(8):1015-1024. (Pubitemid 29200984)
46. Naito A, Azuma S, Tanaka S et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4(6):353-362. (Pubitemid 29359450)
47. Kobayashi N, Kadono Y, Naito A et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 2001;20(6):1271-1280. (Pubitemid 32233967)
48. Kobayashi T, Walsh PT, Walsh MC et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003;19(3):353-363. (Pubitemid 37153412)
49. Franzoso G, Carlson L, Xing L et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997;11(24):3482-3496. (Pubitemid 28023969)
50. Iotsova V, Caamano J, Loy J et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997;3(11):1285-1289. (Pubitemid 27508833)
51. Wong BR, Besser D, Kim N et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999;4(6):1041-1049. (Pubitemid 30054909)
52. Arron JR, Vologodskaia M, Wong BR et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001;276(32):30011- 30017.
53. Soriano P, Montgomery C, Geske R et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64(4):693-702. (Pubitemid 121001157)
54. Wada T, Nakashima T, Oliveira-dos-Santos AJ et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med 2005;11(4):394-399. (Pubitemid 40562329)
55. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T-cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186(12):2075-2080. (Pubitemid 28013694)
56. Bachmann MF, Wong BR, Josien R et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189(7):1025-1031. (Pubitemid 29169819)
57. Josien R, Wong BR, Li HL et al. TRANCE, a TNF family member, is differentially expressed on T-cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162(5):2562-2568. (Pubitemid 29309274)
58. Josien R, Li HL, Ingulli E et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000;191(3):495-502.
59. Emery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273(23):14363-14367. (Pubitemid 28319153)
60. Yun TJ, Chaudhary PM, Shu GL et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998;161(11):6113-6121. (Pubitemid 28535982)
61. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 1999;77(2):188-193. (Pubitemid 29167060)
62. Kim N, Odgren PR, Kim DK et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97(20):10905-10910.
63. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T-cells in immunological tolerance to self and nonself. Nat Immunol 2005;6(4):345-352. (Pubitemid 41716771)
64. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711. (Pubitemid 37174545)
65. Mehling A, Loser K, Varga G et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 2001;194(5):615-628. (Pubitemid 32844772)
66. Loser K, Mehling A, Loeser S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006;12(12):1372-1379. (Pubitemid 44924495)
67. Kong YY, Feige U, Sarosi I et al. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402(6759):304-309.
68. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270(5238):985- 988.
69. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85(3):307-310. (Pubitemid 26160702)
70. Takayanagi H, Oda H, Yamamoto S et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997;240(2):279-286. (Pubitemid 27523651)
71. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T-cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35(7):729-735.
72. Bendele A, McComb J, Gould T et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 1999;27(1):134-142. (Pubitemid 29075759)
73. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440. (Pubitemid 26130190)
74. Muller-Ladner U, Gay RE, Gay S. Molecular biology of cartilage and bone destruction. Curr Opin Rheumatol 1998;10(3):212-219. (Pubitemid 28286811)
75. Kouskoff V, Korganow AS, Duchatelle V et al. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87(5):811-822. (Pubitemid 26404281)
76. Korganow AS, Ji H, Mangialaio S et al. From systemic T-cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10(4):451-461. (Pubitemid 29205481)
77. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159(5):1689-1699. (Pubitemid 33062512)
78. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10(13):4025-4031. (Pubitemid 21905432)
79. Mori H, Kitazawa R, Mizuki S et al. RANK ligand, RANK and OPG expression in type II collageninduced arthritis mouse. Histochem Cell Biol 2002;117(3):283-292. (Pubitemid 34253333)
80. Redlich K, Hayer S, Maier A et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46(3):785-792. (Pubitemid 34214261)
81. Romas E, Sims NA, Hards DK et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161(4):1419-1427.
82. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15(3):280-287. (Pubitemid 36532608)
83. Kotake S, Udagawa N, Hakoda M et al. Activated human T-cells directly induce osteoclastogenesis from human monocytes: possible role of T-cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44(5):1003-1012. (Pubitemid 32433604)
84. Takayanagi H, Iizuka H, Juji T et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43(2):259-269. (Pubitemid 30395733)
85. Oliveri MB, Mautalen CA, Rodriguez Fuchs CA et al. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J 1991;39(1):45-48.
86. Stellon AJ, Davies A, Compston J et al. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 1985;89(5):1078-1083. (Pubitemid 16231573)
87. Piepkorn B, Kann P, Forst T et al. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997;29(11):584-591. (Pubitemid 28053672)
88. Seitz M, Hunstein W. Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Ann Rheum Dis 1985;44(7):438-445. (Pubitemid 15071689)
89. Ebeling PR, Erbas B, Hopper JL et al. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 1998;13(8):1283-1289. (Pubitemid 28373330)
90. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006;12(20 Pt 2):6305s-6308s. (Pubitemid 44703808)
91. Teng YT, Nguyen H, Gao X et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106 (6):R59-67.
92. Mahamed DA, Marleau A, Alnaeeli M et al. G (-) anaerobes-reactive CD4+ T-cells trigger RANKLmediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 2005;54(5):1477-1486. (Pubitemid 40586680)
93. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43(6):1346-1352. (Pubitemid 30416320)
94. Takayanagi H, Ogasawara K, Hida S et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408(6812):600-605.
95. Vermeire K, Heremans H, Vandeputte M et al. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997;158(11):5507- 5513. (Pubitemid 127681260)
96. Manoury-Schwartz B, Chiocchia G, Bessis N et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997;158(11):5501-5506. (Pubitemid 127681259)
97. Horwood NJ, Elliott J, Martin TJ et al. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001;166(8):4915-4921. (Pubitemid 32280701)
98. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001;107(11):1375-1385. (Pubitemid 32522031)
99. Bendixen AC, Shevde NK, Dienger KM et al. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 2001;98(5):2443-2448. (Pubitemid 32209501)
100. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T-cell subset that links T-cell activation and bone destruction. J Exp Med 2006;203(12):2673-2682. (Pubitemid 44833343)
101. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T-cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6(11):1123-1132. (Pubitemid 41541790)
102. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T-cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6(11):1133-1141. (Pubitemid 41541791)
103. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol. 2006;6(4):329-333.
104. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103(9):1345-1352. (Pubitemid 29218305)
105. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006.
106. McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-831. (Pubitemid 43290920)
107. Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12(4):1221-1228. (Pubitemid 43342512)
108. Lane NE, Iannini M, Atkins C et al. RANKL Inhibition with Denosumab Decreases Markers of Bone and Cartilage Turnover in Patients with Rheumatoid Arthritis. Arthritis Rheum 2006;54(9 (Supplement)):S225-226.
109. Dore R, Hurd E, Palmer W et al. Denosumab Increases Bone Mineral Density in Patients With Rheumatoid Arthritis. Arthritis Rheum. 2006;54(9 (Supplement)):S240.
110. Cohen SB, Valen P, Ritchlin C et al. RANKL Inhibition with Denosumab Reduces Progression of Bone Erosions in Patients with Rheumatoid Arthritis: Month 6 MRI Results. Arthritis Rheum 2006;54(9 (Supplement)):S831-832.
111. Hofbauer LC, Dunstan CR, Spelsberg TC et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2 and cytokines. Biochem Biophys Res Commun 1998;250(3):776-781. (Pubitemid 28484803)
112. Hofbauer LC, Khosla S, Dunstan CR et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140(9):4367-4370. (Pubitemid 30647136)
113. Brandstrom H, Jonsson KB, Vidal O et al. Tumor necrosis factor-alpha and-beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998;248(3):454-457. (Pubitemid 28404440)
114. Hofbauer LC, Lacey DL, Dunstan CR et al. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25(3):255-259. (Pubitemid 29406050)
115. Vidal ON, Sjogren K, Eriksson BI et al. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998;248(3):696-700. (Pubitemid 28404484)
116. Palmqvist P, Persson E, Conaway HH et al. IL-6, leukemia inhibitory factor and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002;169(6):3353-3362. (Pubitemid 35013185)
117. Takai H, Kanematsu M, Yano K et al. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998;273(42):27091-27096. (Pubitemid 28500414)
118. Rubin J, Ackert-Bicknell CL, Zhu L et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002;87(9):4273-4279.
119. Vidal NO, Brandstrom H, Jonsson KB et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 1998;159(1):191-195. (Pubitemid 28459282)
120. Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140(10):4382-4389. (Pubitemid 30666099)
121. Hofbauer LC, Shui C, Riggs BL et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280(1):334-339. (Pubitemid 32917516)
122. Brandstrom H, Jonsson KB, Ohlsson C et al. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun 1998;247(2):338-341. (Pubitemid 28420824)
123. Murakami T, Yamamoto M, Ono K et al. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998;252(3):747-752. (Pubitemid 28556848)
124. Takami M, Takahashi N, Udagawa N et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000;141(12):4711-4719. (Pubitemid 32055151)
125. Nagasawa T, Kobayashi H, Kiji M et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002;130(2):338-344. (Pubitemid 35286224)